Ovarian tumor antigens.
Evidence has been reported for at least two common tumor-associated antigens, or antigenic determinants, in human cystadenocarcinomas of the ovary that are apparently absent in tissues of normal reproductive organs. These antigenic determinants are immunologically distinct from carcinoembryonic antigen, alpha-fetoprotein, ferritins and histocompatibility antigens. One of these two ovarian cystadenocarcinoma-associated antigens (OCAA) is not detectable in any ovarian carcinomas except serous or mucinous types, other gynecologic or nongynecologic malignancies thus far tested, while the second antigen is present in about 90% of all gynecologic tumors and occasionally in breast and colon tumors. OCAA has been purified and partially characterized. It is a high molecular weight glycoprotein which carries the unique ovarian tumor-specific antigenic determinant along with some normal cross-reacting determinants. High levels of this glycoprotein antigen have been detected in the sera of ovarian cancer patients with advanced disease by the radioimmunoassay inhibition technique. The serial determination of circulating OCAA appeared to correlate with tumor volume as well as the clinical status of the patients.
D000951:Antigens, Neoplasm; D003536:Cystadenocarcinoma / Q000276:immunology* / Q000473:pathology; D000939:Epitopes; D005260:Female; D005500:Follow-Up Studies; D005833:Genital Neoplasms, Female / Q000276:immunology; D006023:Glycoproteins; D006801:Humans; D008970:Molecular Weight; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000473:pathology; D011863:Radioimmunoassay
D000951:Antigens, Neoplasm; D000939:Epitopes; D006023:Glycoproteins